Paper Review Records
全部论文审稿周期
15 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期；保留 PDF/DOI/网页源链接
160
天
Precision neoadjuvant treatment with AI-assisted subtyping in HR+/HER2−breast cancer: A randomized, phase 2 trial FASCINATE-N
作者
Jun-Jie Li; Lin-Xiaoxi Ma; Peng Ji; Li Chen; Jiong Wu; Guang-Yu Liu; Yi-Feng Hou; Gen-Hong Di; Zhen Hu; Yi-Zhou Jiang; Lei Fan; Zhong-Hua Wang; Ke-Da Yu; Zhi-Ming Shao展开收起
作者单位
Department of Breast Surgery, Fudan University Shanghai Cancer Center, Key Laboratory of Breast Cancer in Shanghai, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China展开收起
323
天
Corpora amylacea profiling reveals disease stage and brain region-specific alterations in glycogen metabolism in Alzheimer’s disease patient brains
作者
Jonathan A.B. Villareal; Tim Bathe; Ana de la Rosa; Rohan V. Sharma; Elvin O. Hernández Gómez; Alison M. Ryan; Tara R. Hawkinson; Anthony M. Tuzzolo; Eduardo Medina-Parrilla; Jennifer L. Phillips; Wangchen Tsering; Andrea A. Iturbe; Benoit I. Giasson; Ramon C. Sun; Matthew S. Gentry; Stefan Prokop展开收起
作者单位
Department of Pathology, Immunology & Laboratory Medicine, University of Florida, Gainesville, FL 32610, USA; Center for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, FL 32610, USA; Department of Neuroscience, University of Florida, Gainesville, FL 32610, USA; Norman Fixel Institute for Neurological Diseases, University of Florida, Gainesville, FL 32608, USA; McKnight Brain Institute, University of Florida, Gainesville, FL 32610, USA; Department of Biochemistry and Molecular Biology, University of Florida, Gainesville, FL 32610, USA; Center for Advanced Spatial Biomolecule Research, University of Florida, Gainesville, FL, USA; Department of Nuclear Medicine, LMU University Hospital, LMU Munich, 81377 Munich, Germany; Graduate School of Systemic Neurosciences (GSN), Department Biology II Neurobiology, LMU Munich, 82152 Planegg-Martinsried, Germany展开收起
213
天
DNA methylation profiling enables subclassification of mucinous ovarian carcinoma and distinguishes it from extraovarian mucinous metastases
作者
Teodor G. Calina; Elena Grafenhorst; Simon Schallenberg; Markus Möbs; Bjarne Daenekas; Alexandru A. Sabo; BaoQing Chen; Ines Koch; Tobias Janik; Michael Churchman; Charlie Gourley; Elizabeth L. Christie; Catalin Vasilescu; Vlad Herlea; Wolfgang D. Schmitt; Nicolae Leopold; Florian Heitz; Angelina Vlaski; Yuri Tolkach; Felix Bremmer; Frederick Klauschen; Reinhard Büttner; Philipp Ströbel; Eike Burandt; Guido Sauter; Frank L. Heppner; Eliane T. Taube; Jalid Sehouli; Ioana E. Braicu; Philipp Euskirchen; David Horst; Kylie L. Gorringe; David Capper; Mihnea P. Dragomir展开收起
作者单位
Faculty of Physics, Babeş-Bolyai University, Cluj-Napoca, Romania; TGC Ventures UG, Berlin, Germany; Institute of Pathology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany; German Cancer Consortium (DKTK), Partner Site Berlin, and German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Neuropathology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany; Department of Pediatric Cardiology, Pulmonology and Pediatric Intensive Care Medicine, University Children’s Hospital Tübingen, Tübingen, Germany; State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangdong Esophageal Cancer Institute, Guangzhou, China; Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China; Nicola Murray Centre for Ovarian Cancer Research, CRUK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, Scotland, UK; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Department of Surgery, Fundeni Clinical Institute, Bucharest, Romania; Department of Pathology, Fundeni Clinical Institute, Bucharest, Romania; Department of Gynecology and Gynecologic Oncology, Evangelische Kliniken Essen-Mitte, Essen, Germany; Institute of Pathology, Ludwig-Maximilians-Universität Munich, Munich, Germany; Institute of Pathology, University Hospital Cologne, Köln, Germany; Institute of Pathology, University Medical Center Göttingen, Göttingen, Germany; Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany; Department of Gynaecology, European Competence Center for Ovarian Cancer, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany; North Eastern German Society for Gynecological Cancer, Tumor Bank Ovarian Cancer Network, Berlin, Germany; Berlin Institute of Health, Berlin, Germany展开收起
353
天
Combination of exosome vaccines, lenvatinib, and anti-PD-1 eradicates tumor in autochthonous hepatocellular carcinoma mice
作者
Bingfeng Zuo; Xuening Liu; Zheng Zhang; Zhenqiang Xu; Yanzhi Zhong; Yang Zhang; Qian Yang; Zezhen Yu; Kangjie Zhao; Yali Zhang; Yiqi Seow; HaiFang Yin展开收起
作者单位
State Key Laboratory of Experimental Hematology & the Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics & Division of Medical Technology & School of Basic Medical Sciences, Tianjin Medical University, Qixiangtai Road, Heping District, Tianjin 300070, China; Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin 300211, China; Genome Institute of Singapore (GIS), Agency for Science, Technology and Research (ASTAR), 60 Biopolis Street, Genome, Singapore 138672, Republic of Singapore展开收起
227
天
Nilotinib induces immunogenic cuproptosis to potentiate cancer immunotherapy
作者
Lei Yao; Deze Zhao; Yu Meng; Yihuang Liu; Hui Su; Danyao Chen; Ziyu Guo; Daishi Li; Linfeng Li; Qian Zhou; Shengchao Xu; Furong Zeng; Xiang Chen; Ledu Zhou; Guangtong Deng展开收起
作者单位
Department of Dermatology, Xiangya Hospital, Central South University, Changsha 410008, China; Department of Hepatic Surgery, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China; Department of Thoracic Surgery, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China; National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha 410008, China; Hunan Engineering Research Center of Skin Health and Disease, Central South University, Changsha 410008, China; Hunan Key Laboratory of Skin Cancer and Psoriasis, Central South University, Changsha 410008, China; National Clinical Research Center of Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, China; Hu Nan Key Laboratory of Aging Biology, Changsha 410008, China; Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan Province 410008, China; Department of Neurosurgery, Xiangya Hospital, Central South University, No.87, Xiangya Road, Changsha, Hunan 410008, China展开收起
411
天
A poly(I:C)/QS-21-based in situ vaccine synergizes with anti-PD-1 therapy to overcome tumor immunoresistance
作者
Wenbo Zhang; Xinrui Ni; Luoyi Zhuo; Jiangrui Liu; Guang Yang; Jianming Li; Lingai Tang; Xiuli Du; Chun Shan; Guoqiang Feng; Wenguang Wang; Qi Gao; Qiang Sui; Min Xia; Chunwang Yuan; Dexiang Chen; Yong Yang; Duowei Wang; Xianjing Li展开收起
作者单位
School of Translational Research, China Pharmaceutical University, Nanjing 211198, China; Shanghai Anyikang Biotechnology Co., LTD, Shanghai 200131, China; Maxvax Biotechnology Co., LTD, Chengdu 610200, China; Center of Interventional Oncology and Liver Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China; Interventional Department of Liver Diseases and Tumors with Integrated Traditional Chinese and Western Medicine, The Second Hospital of Hohhot, Hohhot 010020, China; School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, China; Center for New Drug Safety Evaluation and Research, China Pharmaceutical University, Nanjing 211198, China展开收起
Expert Matching · Case Demo
把投稿要求，转成可验证的期刊方案
说清专业、时限和作者背景，CrushSCI 结合真实审稿样本，给出拟题方向、期刊初筛与周期判断。
客户询问
我是环境工程专业，需要一篇 SCI，希望 3 个月内见刊。没有基金，也没有大牛挂名，可以投哪些期刊？
CrushSCI回复
可以。先按 90 天时限做可行性筛选，同步查找无基金、无知名作者挂靠的典型论文案例，作为选刊依据。重点核对研究质量与期刊 scope。
- 拟题建议
- 《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》
样本口径2026 年最近 5 篇有效论文样本
平均审稿62 天
中位数65 天